ASLAN Pharmaceuticals’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

ASLAN is a is a biotechnology company that develops novel medicines for the treatment of oncology and immunology. Read more

ASLAN is a is a biotechnology company that develops novel medicines for the treatment of oncology and immunology. Read more

Carl Firth's photo - Founder & CEO of ASLAN Pharmaceuticals

Founder & CEO

Carl Firth

CEO Approval Rating

83/100

Founded:

2010

Status:

PublicNASDAQASLN

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Agios is ASLAN Pharmaceuticals's top competitor. Agios is headquartered in Cambridge, Massachusetts, and was founded in 2008. Like ASLAN Pharmaceuticals, Agios also operates in the Biotechnology field. Agios generates 6,196% the revenue of ASLAN Pharmaceuticals.

Cleveland BioLabs is seen as one of ASLAN Pharmaceuticals's top competitors. Cleveland BioLabs's headquarters is in Buffalo, New York, and was founded in 2003. Cleveland BioLabs is in the Pharmaceuticals field. Cleveland BioLabs generates 28% of ASLAN Pharmaceuticals's revenue.

ArQule has been one of ASLAN Pharmaceuticals's top competitors. ArQule was founded in 1993, and its headquarters is in Burlington, Massachusetts. ArQule competes in the Pharmaceuticals industry. ArQule has 1 more employees than ASLAN Pharmaceuticals.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Galena Biopharma a competitor of ASLAN Pharmaceuticals?

Quarterly and Annual Revenue

Coming soon for ASLAN Pharmaceuticals!

Annual Revenue

$3M

ASLAN Pharmaceuticals's revenue is the ranked 8th among it's top 10 competitors. The top 10 competitors average 2.1B.

Acquisitions

No recent acquisitions found related to ASLAN Pharmaceuticals

ASLAN Pharmaceuticals Funding History

$12M$34M$68M$100M$142M$145M

Since ASLAN Pharmaceuticals was founded in 2010, it has participated in 7 rounds of funding. In total ASLAN Pharmaceuticals has raised $145.0M. ASLAN Pharmaceuticals' last funding round was on Oct 2019 for a total of $3.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Debt
Oct 2019
$3M
-
IPO
May 2018
$42M

Series D
Jul 2016
$23M

TopTaiwan

Series C
Jan 2016
$9M
Series C
Dec 2015
$34M

Since ASLAN Pharmaceuticals was founded in 2010, it has participated in 7 rounds of funding. In total ASLAN Pharmaceuticals has raised $145.0M. ASLAN Pharmaceuticals' last funding round was on Oct 2019 for a total of $3.0M

Investments

No recent investments found related to ASLAN Pharmaceuticals

ASLAN Pharmaceuticals News

October 16, 2020ChinaBio Today

Aslan Pharma Repurposes DHODH Inhibitor for Autoimmune, COVID-19 Indications

Singapore's Aslan Pharma announced plans to develop ASLAN003, its next-gen dihydroorotate dehydrogena... See more »
September 25, 2020MarketScreener

2020 Second Extraordinary General Meeting Minutes

(marketscreener.com) Non-current ...https://www.marketscreener.com/quote/stock/ASLAN-PHARMACEUTICALS-... See more »
September 10, 2020Micro Small Cap

ASLAN Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference

SINGAPORE, Sept. 10, 2020 (GLOBE NEWSWIRE) - ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage im... See more »
August 24, 2020FierceBiotech

Aslan hopes to roar again as Dupixent rival test resumes after COVID-19 chaos

Aslan hopes to roar again as Dupixent rival test resumes after COVID-19 chaos badams Mon, 08/24/2020 ... See more »
August 7, 2020Markets Insider

ASLAN Pharmaceuticals to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference 2020 | Markets Insider

SINGAPORE, Aug. 07, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinic... See more »
August 2, 2020FierceBiotech

Aslan hires Kobayashi to add IL-13 clinical trial expertise

Aslan hires Kobayashi to add IL-13 clinical trial expertise ntaylor Mon, 08/03/2020 - 08:59... See more »

ASLAN Pharmaceuticals Press Releases

May 10, 2019GlobalNewswire

ASLAN Pharmaceuticals' Varlitinib Selected by Leading Korean Gastric Cancer Group for Study in Second-Line Gastric Cancer

- K-MASTER, Korea's leading precision medicine research group, to conduct phase 1b/2 umbrella study t... See more »
March 29, 2019GlobeNewswire

ASLAN Pharmaceuticals Completes First Part of Single Ascending Dose Study for ASLAN004 Targeting Atopic Dermatitis

Interim results support competitive efficacy, potential for monthly dosing and favourable safety prof... See more »
January 15, 2019CENTRALCHARTS

ASLAN Pharmaceuticals to Present Positive varlitinib Data in First-Line Biliary Tract Cancer in Combination With Chemotherapy at ASCO GI

ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting ... See more »
January 14, 2019StreetInsider

ASLAN Pharmaceuticals to Present Positive varlitinib Data in First-Line Biliary Tract Cancer in Combination With Chemotherapy at ASCO GI

SINGAPORE, Jan. 15, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinic... See more »
January 13, 2019StreetInsider

ASLAN Pharmaceuticals Announces Study Results from Phase 2 Study of Varlitinib in First-line Gastric Cancer

SINGAPORE, Jan. 14, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinic... See more »
January 11, 2019CentralCharts

ASLAN Pharmaceuticals Announces Study Results from Phase 2 Study of Varlitinib in First-line Gastric Cancer

ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting ... See more »
January 2, 2019centralcharts

ASLAN Pharmaceuticals Completes Enrolment for Global Pivotal TreeTopp Study Ahead of Schedule

SINGAPORE, Jan. 02, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinic... See more »

ASLAN Pharmaceuticals Videos

Headquarters

83 Clemenceau Avenue Suite 12-03 UE Square

Singapore, Central Singapore239920

65-6222-4235

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

ASLAN is a is a biotechnology company that develops novel medicines for the treatment of oncology and immunology. ASLAN Pharmaceuticals was founded in 2010. ASLAN Pharmaceuticals' headquarters is located in Singapore, Central Singapore, SG 239920. It ...

CEO

ASLAN Pharmaceuticals's Founder & CEO, Carl Firth, currently has an approval rating of 83%. ASLAN Pharmaceuticals's primary competitors are Agios, Cleveland BioLabs & ArQule.

Website

aslanpharma.com

Frequently Asked Questions about ASLAN Pharmaceuticals

  1. When was ASLAN Pharmaceuticals founded?

    ASLAN Pharmaceuticals was founded in 2010
  2. Who is ASLAN Pharmaceuticals's CEO?

    ASLAN Pharmaceuticals's CEO is Carl Firth
  3. How much revenue does ASLAN Pharmaceuticals generate?

    ASLAN Pharmaceuticals generates $3M in revenue
  4. How much funding does ASLAN Pharmaceuticals have?

    ASLAN Pharmaceuticals has historically raised $145M in funding
  1. Where is ASLAN Pharmaceuticals's headquarters?

    ASLAN Pharmaceuticals's headquarters is in Singapore Central Singapore, SG
  2. How many employees does ASLAN Pharmaceuticals have?

    ASLAN Pharmaceuticals has 23 employees
  3. What sector does ASLAN Pharmaceuticals operate in?

    ASLAN Pharmaceuticals is in Biotechnology
  4. Who are ASLAN Pharmaceuticals's competitors?

    ASLAN Pharmaceuticals's top competitors are Agios, Cleveland BioLabs, ArQule